Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers Jg. 12; H. 6; S. 1449
Hauptverfasser: Mollica, Veronica, Rizzo, Alessandro, Montironi, Rodolfo, Cheng, Liang, Giunchi, Francesca, Schiavina, Riccardo, Santoni, Matteo, Fiorentino, Michelangelo, Lopez-Beltran, Antonio, Brunocilla, Eugenio, Brandi, Giovanni, Massari, Francesco
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI 02.06.2020
Schlagworte:
Review
urothelial carcinoma
immunotherapy
PD-L1
antibody drug conjugates
clinical trials
immune checkpoint inhibitors
FGFR
PD-1
ISSN:2072-6694, 2072-6694
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In recent years, the better understanding of the role of immune system in cancer control has led to the development and approval of several immunotherapeutic approaches in UC therapy, where immune checkpoint inhibitors have been revolutionizing the treatment of metastatic UC. Because of a better tumor molecular profiling, FGFR inhibitors, PARP inhibitors, anti-HER2 agents, and antibody drug conjugates targeting Nectin-4 are also emerging as new therapeutic options. Moreover, a wide number of trials is ongoing with the aim to evaluate several other alterations and pathways as new potential targets in metastatic UC. In this review, we will discuss the recent advances and highlight future directions of the medical treatment of UC, with a particular focus on recently published data and ongoing active and recruiting trials.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
These authors contribution is equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12061449